Dermapharm Holding SE
DMP
ISIN DE000A2GS5D8 / Valor 40166352
Dermapharm Holding SE
UMushroom community rating:
About company
Dermapharm Holding SE is a pharmaceutical company that operates through its subsidiary HÜBNER Naturarzneimittel GmbH, also known as MEDOPHARM Arzneimittel GmbH & Co. KG. Founded in 1932 in Munich, the company specializes in natural preparations for pharmacies, particularly silica products. Dermapharm is a leading manufacturer of branded pharmaceuticals, medical devices, and food supplements, with a focus on steroids, dermatics, and painkillers. The company's integrated business model includes in-house development, production, and distribution of healthcare products in Germany, Europe, and the United States. With a strong emphasis on innovation and rapid growth, Dermapharm is dedicated to providing high-quality pharmaceuticals and healthcare products to its customers.
Summarized from source with an LLMView SourceSector: HealthcareLatest Results (07.01.2025):
Revenue Growth
In the latest financial results for the first quarter of 2023, Dermapharm Holding SE reported a revenue of EUR 1,135.4 million. This marks an increase compared to the previous year's revenue of EUR 1,024.8 million for the same period, indicating a positive growth trajectory for the company.
EBITDA Performance
Dermapharm Holding SE's adjusted EBITDA for Q1 2023 was EUR 310.2 million, with an adjusted EBITDA margin of 27.3%. This is a decrease from the previous year's adjusted EBITDA of EUR 359.8 million and a margin of 35.1%, reflecting changes in operational efficiency or cost structures.
Profitability
The profit for the period in Q1 2023 for Dermapharm Holding SE was EUR 60.5 million, down from EUR 132.6 million in the same quarter of the previous year. This decline in profitability is also reflected in the earnings per share, which decreased from EUR 2.49 to EUR 1.16.
Dividend Announcement
For the first quarter of 2023, Dermapharm Holding SE declared a dividend of EUR 0.88 per share. This is slightly lower than the EUR 1.05 dividend per share announced in the same period of the previous year, aligning with the overall decrease in profitability.
Financial Position
As of Q1 2023, Dermapharm Holding SE's balance sheet showed total equity of EUR 545.0 million, with an equity ratio of 25.2%. The company's net debt increased to EUR 936.6 million, compared to EUR 367.8 million in the previous year, indicating a significant rise in leverage.
Summarized from source with an LLMView SourceKey figures
Performance
Volatility
2155 M
Market cap (USD)
130,224
Daily traded volume (Shares)
38.55 / 37.75
1 day high/low (USD)
52 weeks high/low (USD)
Dividend ex-date
Dividend (USD)
Dividend yield (p.a.)
Est dividend (USD)
Est dividend yield
P/E ratio
Est P/E ratio
EPS (USD)
Est EPS (USD)
Ratings & reviews
EQUITIES OF THE SAME SECTOR
